/

NKTR

Nektar TherapeuticsOpen

38.32−1.52 −3.82%USD

NasdaqCM · as of Oct 13, 12:40 ET · 15m delay

Open

39.65

Prev close

39.84

Day range

38.0739.83

52-week range

33.40109.00

Volume

387.19K0.36×

Mkt cap

1.31B

P/E ttm

—

Fwd P/E

-3.72

EPS ttm

-18.96

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−64.84%

Price Chart

Yahoo Finance · delayed

NKTROct 13, 2026O 39.65H 39.83L 38.07C 38.32−1.52 (−3.82%)Vol 387.19K

SMA 5065.21
SMA 20065.24

1Y change −29.48% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NKTR Nektar Therapeutics · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.98%
1 month: −45.07%
3 months: −42.95%
6 months: −52.84%
Year to date: −9.37%
1 year: −33.24%

Valuation & ownership

Market cap: 1.31B
Enterprise value: 811.85M
P/E (ttm): —
Forward P/E: -3.72
PEG ratio: 0.31
Price / book: 1.45
Price / sales (ttm): 23.97
EV / EBITDA: -6.25
EPS (ttm): -18.96
EPS (forward): -10.30
Beta (5y monthly): 1.27
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 34.14M
Float: 28.22M
Short % of float: 22.50%
Short ratio (days): 5.30
Held by insiders: 0.38%
Held by institutions: 107.08%
Avg volume (3m): 1.09M
50-day average: 65.85
200-day average: 65.27
52-week change: −33.24%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 20.7
vs 50-day SMA: −41.23%
vs 200-day SMA: −41.26%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.92%
Realised vol (20d, ann.): 103.4%
From 52-week high: −64.84%
From 52-week low: +14.73%

ANR

Analyst Consensus

12 analysts

Consensus

Buy

1.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

133.08

+247.29% implied

Low 50.00Median 150.00High 192.00

Recommendation trend

Now11 / 4 / 0
1m ago / 2 /

DES

About Nektar Therapeutics

Yahoo Finance profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 63
Headquarters: San Francisco, CA, United States
Website: nektar.com
Officers: Mr. Howard W. Robin CEO, President & Director
Dr. Jonathan Zalevsky Ph.D. Senior VP and Chief Research & Development Officer
Ms. Linda M. Rubinstein M.A. CFO and Principal Financial & Accounting Officer
Mr. Jason Barnard

SEAS

Seasonality · NKTR

2007–2026 · monthly returns

Strongest month Nov +7.37%Weakest month May −4.10%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.7	84.8	4.3	18.2	-23.7	7.6	1.2	1.0	-15.2	-36.7			−9.4%
2025	-10.8	1.2	-19.0	17.6	-10.0	139.3	-16.1	37.7	90.6	14.1	0.4	-35.2	+203.1%
2024	-3.6	31.5	31.0	57.0	-13.0	-2.4	8.1	-4.5	1.6	-8.5	-4.2	-18.4	+66.1%
2023	20.4	-49.3	-49.3	7.1	-22.7	0.0	-6.9	11.1	0.0	-21.7	4.3	14.3	−75.2%
2022	-17.7	-7.9	-47.4	-23.4	-15.7	9.2	4.2	-0.5	-18.8	17.5	-25.5	-19.3	−83.3%
2021	15.9	15.2	-11.9	-2.0	-7.9	-5.0	-8.0	-2.0	16.0	-15.6	-25.7	20.0	−20.5%
2020	-7.9	4.6	-14.2	7.6	13.0	6.7	-4.3	-12.7	-14.2	-4.5	3.5	3.7	−21.3%
2019	28.8	-4.3	-17.1	-4.7	-2.2	13.6	-20.0	-38.3	3.7	-6.0	18.4	6.4	−34.3%
2018	40.0	3.5	22.8	-21.3	-4.1	-39.2	7.7	26.4	-8.3	-36.5	4.4	-18.6	−45.0%
2017	-1.3	8.0	79.4	-19.2	4.8	-1.7	11.7	-3.7	14.1	0.4	124.1	10.6	+386.7%
2016	-19.1	-18.1	23.1	14.0	-1.5	-7.8	21.5	3.2	-3.8	-27.8	-0.9	-0.2	−27.2%
2015	-5.5	-10.7	-15.8	-13.5	20.8	8.8	0.8	-12.4	-0.8	8.3	31.9	7.6	+8.7%
2014	19.8	-5.7	-5.5	-2.9	-0.3	9.3	-17.7	35.2	-15.4	14.3	20.9	-7.0	+36.6%
2013	15.7	8.2	18.7	-1.5	-12.6	22.0	-2.9	8.7	-14.2	-9.0	32.1	-9.6	+53.2%
2012	11.6	14.7	10.5	-3.7	-12.2	20.4	5.6	0.7	24.5	-15.7	-27.6	13.7	+32.3%
2011	-12.8	-14.5	-1.3	9.6	-6.7	-24.9	-11.4	-11.0	-15.4	11.8	-7.7	12.0	−56.4%
2010	22.5	8.5	22.8	-8.2	-12.4	-1.1	7.9	-2.1	15.5	-1.4	-13.0	1.4	+37.9%
2009	-26.1	9.2	20.0	3.9	20.5	-4.0	9.3	17.1	17.5	-16.6	7.3	7.0	+67.6%
2008	6.3	-2.5	-0.1	-30.5	-7.5	-24.9	48.7	-20.3	-9.6	54.0	-14.1	17.1	−17.1%
2007	-16.5	-6.6	10.1	-5.3	-8.3	-16.3	-19.6	8.3	6.9	-32.3	11.5	0.6	−55.9%

INSD

Insider Activity · NKTR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 17, 2026	Robin Howard WChief Executive Officer	Sale at price 71.98 per share.	418	$30.09K
Aug 17, 2026	Zalevsky JonathanOfficer	Sale at price 71.98 per share.	186	$13.39K
Jun 29, 2026	Zalevsky JonathanOfficer	Sale at price 70.00 per share.	5.7K	$397.67K
Jun 16, 2026	Robin Howard WChief Executive Officer	Sale at price 59.97 - 61.65 per share.	20K	$1.22M
Jun 14, 2026	Zalevsky JonathanOfficer	Sale at price 60.71 per share.	5.5K	$336.21K
May 18, 2026	Robin Howard WChief Executive Officer	Sale at price 65.51 per share.	444	$29.09K
May 18, 2026	Zalevsky JonathanOfficer	Sale at price 65.51 per share.	199	$13.04K
Feb 17, 2026	Robin Howard WChief Executive Officer	Sale at price 73.00 per share.	423	$30.88K
Feb 17, 2026	Zalevsky JonathanOfficer	Sale at price 73.00 per share.	180	$13.14K
Jan 19, 2026	Zalevsky JonathanOfficer	Sale at price 35.67 per share.	3.9K	$137.94K
Dec 21, 2025	Robin Howard WChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	21.7K	—
Dec 21, 2025	Zalevsky JonathanOfficer	Stock Award(Grant) at price 0.00 per share.	6.3K	—
Nov 24, 2025	Robin Howard WChief Executive Officer	Sale at price 54.28 per share.	2.2K	$119.80K
Nov 24, 2025	Zalevsky JonathanOfficer	Sale at price 54.28 per share.	1.2K	$62.80K
Nov 24, 2025	Wilson Mark AndrewOfficer	Sale at price 54.28 per share.	630	$34.20K
Nov 20, 2025	Robin Howard WChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	7.1K	—
Nov 20, 2025	Wilson Mark AndrewOfficer	Stock Award(Grant) at price 0.00 per share.	1.9K	—
Nov 20, 2025	Zalevsky JonathanOfficer	Stock Award(Grant) at price 0.00 per share.	2.7K	—
Sep 8, 2025	Robin Howard WChief Executive Officer	Sale at price 45.16 - 48.18 per share.	6.7K	$311.21K
Sep 4, 2025	Robin Howard WChief Executive Officer	Sale at price 32.37 - 39.89 per share.	11.8K	$430.96K

NKTR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NKTR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Nektar Therapeutics

Seasonality · NKTR

Insider Activity · NKTR

Congress Trades · NKTR

Investors Holding NKTR

Investors Holding NKTR

Congress Trades · NKTR

Insider Activity · NKTR

Seasonality · NKTR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Nektar Therapeutics

Financial Snapshot

Earnings & Dividends

News